Cellanyx
Cellanyx is developing the next generation cancer diagnostic. Cellanyx leverages advances in matrix biology, nanomedicine, and classical techniques in engineering, computer science and mathematics to provide a sensitive, objective and predictive solution to cancer diagnosis. Cancer Diagnostics Patients who are diagnosed with prostate, skin, and breast cancer, are being monitored and/or are surgical candidates will benefit from Cellanyx's technology. Cellanyx's test ordered (at diagnosis) can provide physicians with objective, prognostic information to assist in their treatment decision process.Cellanyx returns two metrics to the practicing physician: the first metric predicts the growth or oncogenic potential of a biopsy, the second metric predicts the metastatic potential of the biopsy. With this information the practicing physician can better assess what treatment plan to pursue. Compound Discovery Cellanyx is also positioned to leverage its technology as a cell-based assay to identify compounds that reduce the growth and metstatic potential of cancer cells, thereby identifying compounds that are less toxic to the body and still effective in slowing down the growth and metastasis of aberrant cancer cells, reverting them, in principal, to a normal state.
Cellanyx
Cellanyx is developing the next generation cancer diagnostic. Cellanyx leverages advances in matrix biology, nanomedicine, and classical techniques in engineering, computer science and mathematics to provide a sensitive, objective and predictive solution to cancer diagnosis. Cancer Diagnostics Patients who are diagnosed with prostate, skin, and breast cancer, are being monitored and/or are surgical candidates will benefit from Cellanyx's technology. Cellanyx's test ordered (at diagnosis) can provide physicians with objective, prognostic information to assist in their treatment decision process.Cellanyx returns two metrics to the practicing physician: the first metric predicts the growth or oncogenic potential of a biopsy, the second metric predicts the metastatic potential of the biopsy. With this information the practicing physician can better assess what treatment plan to pursue. Compound Discovery Cellanyx is also positioned to leverage its technology as a cell-based assay to identify compounds that reduce the growth and metstatic potential of cancer cells, thereby identifying compounds that are less toxic to the body and still effective in slowing down the growth and metastasis of aberrant cancer cells, reverting them, in principal, to a normal state.